Tue, Oct 21, 2014, 8:07 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • clsn_bounce_starts_now clsn_bounce_starts_now Jun 7, 2013 1:54 AM Flag

    "Hisun and Celsion have agreed that the technology development contract will remain in effect while the parties continue to collaborate and are evaluating next steps in relation to ThermoDox®, which include the sub-group analysis of patients in the HEAT study and other activities to further the development of ThermoDox® for the China territory."

    BANG! Half the world HCC cases occur in China. Hisun is pushing China SFDA for the approval of Thermodox based on the 66% overall survival improvement based on the 300 patient subgroup. That's all you need to know. Thermodox is a multi billion dollar drug in China alone. There is currently NO standard of care for HCC in China. They are loaded with money and looking to DO SOMETHING about HCC in China. Hisun pharmaceuticals already invested 5 million dollars with Celsion, and they want a return on that money.

    The Chinese government is very friendly to Chinese companies (as many of them are partly state owned, Hisun no exception), and people are dropping dead of HCC left and right everyday in China's 1.3 billlion population.

    No brainer. They will let the data come out Jun 19th at ECIO, and then they will file for approval in China. Expect royalties to start flowing by the end of the summer.

    And that is just ONE drug, in one location. Don't forget you need to store these little nano liposomal formulations, and the only people with the PATENTS granted in Asia is CELSION. Anyone who wants to use the technology to store ANY liposomally encapsulated drug, from ANY company, will have to pay Celsion a royalty.

    At this point, I don't even think Celsion can stay as a standalone public company. It's just a matter of time before they get aquired. All that remains is to determing the price.

    Back in the day Imclone was aquired for 7 billion dollars just for one drug, Erbitux, than extended prostate cancer life by just 4 months.

    So what do you think Thermodox is worth? Pluse the liposomal encapsulation technology? Pluse the storage patents? Plus the two other ongoing phase 2 trials?

    A LOT!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wow this new Trend Signal Mobile App is pretty Accurate it uses formulas based on months of the stocks history volume news etc to determine whether a stock is a Potential Buy Sell or a Hold... awesome stuff

      Text the word TRADES to 99158 to download a free copy

    • BUY CLSN BUY

    • Half the world HCC cases occur in China. Hisun is pushing China SFDA for the approval of Thermodox based on the 66% overall survival improvement based on the 300 patient subgroup. That's all you need to know. Thermodox is a multi billion dollar drug in China alone. There is currently NO standard of care for HCC in China. They are loaded with money and looking to DO SOMETHING about HCC in China. Hisun pharmaceuticals already invested 5 million dollars with Celsion, and they want a return on that money.

      The Chinese government is very friendly to Chinese companies (as many of them are partly state owned, Hisun no exception), and people are dropping dead of HCC left and right everyday in China's 1.3 billlion population.

      No brainer. They will let the data come out Jun 19th at ECIO, and then they will file for approval in China. Expect royalties to start flowing by the end of the summer.

      And that is just ONE drug, in one location. Don't forget you need to store these little nano liposomal formulations, and the only people with the PATENTS granted in Asia is CELSION. Anyone who wants to use the technology to store ANY liposomally encapsulated drug, from ANY company, will have to pay Celsion a royalty.

      At this point, I don't even think Celsion can stay as a standalone public company. It's just a matter of time before they get aquired. All that remains is to determing the price.

      Back in the day Imclone was aquired for 7 billion dollars just for one drug, Erbitux, than extended prostate cancer life by just 4 months.

      So what do you think Thermodox is worth? Pluse the liposomal encapsulation technology? Pluse the storage patents? Plus the two other ongoing phase 2 trials?

      A LOT!
      .

    • Half the world HCC cases occur in China. Hisun is pushing China SFDA for the approval of Thermodox based on the 66% overall survival improvement based on the 300 patient subgroup. That's all you need to know. Thermodox is a multi billion dollar drug in China alone. There is currently NO standard of care for HCC in China. They are loaded with money and looking to DO SOMETHING about HCC in China. Hisun pharmaceuticals already invested 5 million dollars with Celsion, and they want a return on that money.

      The Chinese government is very friendly to Chinese companies (as many of them are partly state owned, Hisun no exception), and people are dropping dead of HCC left and right everyday in China's 1.3 billlion population.

      No brainer. They will let the data come out Jun 19th at ECIO, and then they will file for approval in China. Expect royalties to start flowing by the end of the summer.

      And that is just ONE drug, in one location. Don't forget you need to store these little nano liposomal formulations, and the only people with the PATENTS granted in Asia is CELSION. Anyone who wants to use the technology to store ANY liposomally encapsulated drug, from ANY company, will have to pay Celsion a royalty.

      At this point, I don't even think Celsion can stay as a standalone public company. It's just a matter of time before they get aquired. All that remains is to determing the price.

      Back in the day Imclone was aquired for 7 billion dollars just for one drug, Erbitux, than extended prostate cancer life by just 4 months.

      So what do you think Thermodox is worth? Pluse the liposomal encapsulation technology? Pluse the storage patents? Plus the two other ongoing phase 2 trials?

      A LOT!

      .

      • 1 Reply to clsn_bounce_starts_now
      • Mr. Hua Bai, CEO and Chairman of Hisun, stated, "We are extremely excited to pursue this arrangement with Celsion. Hisun is well positioned to provide ThermoDox® — potentially one of the most important and innovative drugs to treat HCC to patients in China, the world's largest market. China is one of the countries with the highest HCC incidence and mortality and, up until now, there has not been any standard of care for treating HCC in China. This joint effort will most likely facilitate the local manufacturing and commercial launch in China, thereby providing physicians with more options for better care and prolonging the survival of HCC patients. In the meantime, we are also hopeful that this collaboration will enable Hisun to increase its focus on more innovative drugs. Given the fact that we are a leading Chinese pharmaceutical company with international standards of R&D and manufacturing technology, Hisun will seek to manufacture and supply the global markets, along with distribution exclusivity in Greater China. This venture will help spearhead Hisun's globalization in manufacturing and commercialization capabilities."

    • Bingo my friend. I am buying much as I can. I am seeing $3.00 soon.

      Sentiment: Strong Buy

    • Of course they agree, they already put down their money, this is old news

    • BANG! Half the world HCC cases occur in China. Hisun is pushing China SFDA for the approval of Thermodox based on the 66% overall survival improvement based on the 300 patient subgroup. That's all you need to know. Thermodox is a multi billion dollar drug in China alone. There is currently NO standard of care for HCC in China. They are loaded with money and looking to DO SOMETHING about HCC in China. Hisun pharmaceuticals already invested 5 million dollars with Celsion, and they want a return on that money.

      The Chinese government is very friendly to Chinese companies (as many of them are partly state owned, Hisun no exception), and people are dropping dead of HCC left and right everyday in China's 1.3 billlion population.

      No brainer. They will let the data come out Jun 19th at ECIO, and then they will file for approval in China. Expect royalties to start flowing by the end of the summer.

      And that is just ONE drug, in one location. Don't forget you need to store these little nano liposomal formulations, and the only people with the PATENTS granted in Asia is CELSION. Anyone who wants to use the technology to store ANY liposomally encapsulated drug, from ANY company, will have to pay Celsion a royalty.

      At this point, I don't even think Celsion can stay as a standalone public company. It's just a matter of time before they get aquired. All that remains is to determing the price.

      Back in the day Imclone was aquired for 7 billion dollars just for one drug, Erbitux, than extended prostate cancer life by just 4 months.

      So what do you think Thermodox is worth? Pluse the liposomal encapsulation technology? Pluse the storage patents? Plus the two other ongoing phase 2 trials?

      A LOT!

      • 2 Replies to clsn_bounce_starts_now
      • Half the world HCC cases occur in China. Hisun is pushing China SFDA for the approval of Thermodox based on the 66% overall survival improvement based on the 300 patient subgroup. That's all you need to know. Thermodox is a multi billion dollar drug in China alone. There is currently NO standard of care for HCC in China. They are loaded with money and looking to DO SOMETHING about HCC in China. Hisun pharmaceuticals already invested 5 million dollars with Celsion, and they want a return on that money.

        The Chinese government is very friendly to Chinese companies (as many of them are partly state owned, Hisun no exception), and people are dropping dead of HCC left and right everyday in China's 1.3 billlion population.

        No brainer. They will let the data come out Jun 19th at ECIO, and then they will file for approval in China. Expect royalties to start flowing by the end of the summer.

        And that is just ONE drug, in one location. Don't forget you need to store these little nano liposomal formulations, and the only people with the PATENTS granted in Asia is CELSION. Anyone who wants to use the technology to store ANY liposomally encapsulated drug, from ANY company, will have to pay Celsion a royalty.

        At this point, I don't even think Celsion can stay as a standalone public company. It's just a matter of time before they get aquired. All that remains is to determing the price.

        Back in the day Imclone was aquired for 7 billion dollars just for one drug, Erbitux, than extended prostate cancer life by just 4 months.

        So what do you think Thermodox is worth? Pluse the liposomal encapsulation technology? Pluse the storage patents? Plus the two other ongoing phase 2 trials?

      • Half the world HCC cases occur in China. Hisun is pushing China SFDA for the approval of Thermodox based on the 66% overall survival improvement based on the 300 patient subgroup. That's all you need to know. Thermodox is a multi billion dollar drug in China alone. There is currently NO standard of care for HCC in China. They are loaded with money and looking to DO SOMETHING about HCC in China. Hisun pharmaceuticals already invested 5 million dollars with Celsion, and they want a return on that money.

        The Chinese government is very friendly to Chinese companies (as many of them are partly state owned, Hisun no exception), and people are dropping dead of HCC left and right everyday in China's 1.3 billlion population.

        No brainer. They will let the data come out Jun 19th at ECIO, and then they will file for approval in China. Expect royalties to start flowing by the end of the summer.

        And that is just ONE drug, in one location. Don't forget you need to store these little nano liposomal formulations, and the only people with the PATENTS granted in Asia is CELSION. Anyone who wants to use the technology to store ANY liposomally encapsulated drug, from ANY company, will have to pay Celsion a royalty.

        At this point, I don't even think Celsion can stay as a standalone public company. It's just a matter of time before they get aquired. All that remains is to determing the price.

        Back in the day Imclone was aquired for 7 billion dollars just for one drug, Erbitux, than extended prostate cancer life by just 4 months.

        So what do you think Thermodox is worth? Pluse the liposomal encapsulation technology? Pluse the storage patents? Plus the two other ongoing phase 2 trials?

        A LOT!

        .

    • BANG! Half the world HCC cases occur in China. Hisun is pushing China SFDA for the approval of Thermodox based on the 66% overall survival improvement based on the 300 patient subgroup. That's all you need to know. Thermodox is a multi billion dollar drug in China alone. There is currently NO standard of care for HCC in China. They are loaded with money and looking to DO SOMETHING about HCC in China. Hisun pharmaceuticals already invested 5 million dollars with Celsion, and they want a return on that money.

      The Chinese government is very friendly to Chinese companies (as many of them are partly state owned, Hisun no exception), and people are dropping dead of HCC left and right everyday in China's 1.3 billlion population.

      No brainer. They will let the data come out Jun 19th at ECIO, and then they will file for approval in China. Expect royalties to start flowing by the end of the summer.

      And that is just ONE drug, in one location. Don't forget you need to store these little nano liposomal formulations, and the only people with the PATENTS granted in Asia is CELSION. Anyone who wants to use the technology to store ANY liposomally encapsulated drug, from ANY company, will have to pay Celsion a royalty.

      At this point, I don't even think Celsion can stay as a standalone public company. It's just a matter of time before they get aquired. All that remains is to determing the price.

      Back in the day Imclone was aquired for 7 billion dollars just for one drug, Erbitux, than extended prostate cancer life by just 4 months.

      So what do you think Thermodox is worth? Pluse the liposomal encapsulation technology? Pluse the storage patents? Plus the two other ongoing phase 2 trials?

      A LOT!

      .

    • BANG! Half the world HCC cases occur in China. Hisun is pushing China SFDA for the approval of Thermodox based on the 66% overall survival improvement based on the 300 patient subgroup. That's all you need to know. Thermodox is a multi billion dollar drug in China alone. There is currently NO standard of care for HCC in China. They are loaded with money and looking to DO SOMETHING about HCC in China. Hisun pharmaceuticals already invested 5 million dollars with Celsion, and they want a return on that money.

      The Chinese government is very friendly to Chinese companies (as many of them are partly state owned, Hisun no exception), and people are dropping dead of HCC left and right everyday in China's 1.3 billlion population.

      No brainer. They will let the data come out Jun 19th at ECIO, and then they will file for approval in China. Expect royalties to start flowing by the end of the summer.

      And that is just ONE drug, in one location. Don't forget you need to store these little nano liposomal formulations, and the only people with the PATENTS granted in Asia is CELSION. Anyone who wants to use the technology to store ANY liposomally encapsulated drug, from ANY company, will have to pay Celsion a royalty.

      At this point, I don't even think Celsion can stay as a standalone public company. It's just a matter of time before they get aquired. All that remains is to determing the price.

      Back in the day Imclone was aquired for 7 billion dollars just for one drug, Erbitux, than extended prostate cancer life by just 4 months.

      So what do you think Thermodox is worth? Pluse the liposomal encapsulation technology? Pluse the storage patents? Plus the two other ongoing phase 2 trials?

      A LOT!

      .

    • Great post!

    • View More Messages
 
CLSN
2.625+0.025(+0.96%)Oct 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.